Radiotherapy in Primary Mediastinal Lymphoma (pml)

This study has been completed.
Sponsor:
Information provided by:
Instituto Mexicano del Seguro Social
ClinicalTrials.gov Identifier:
NCT01230008
First received: October 27, 2010
Last updated: NA
Last verified: June 2009
History: No changes posted
  Purpose

The use of Rituximab has been proposed to be useful and avoid the use of radiotherapy in diffuse large B-cell lymphoma with bulky disease.We assess efficacy of adjuvant radiotherapy in patients treated with R-CHOP


Condition Intervention
Adjuvant Radiotherapy on Complete Remission Patients
Radiation: no drugs

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Adjuvant Radiotherapy in Primary Mediastinal Lymphoma in Patients That Received R-CHOP

Resource links provided by NLM:


Further study details as provided by Instituto Mexicano del Seguro Social:

Primary Outcome Measures:
  • measurement of progression free-survival and overall survival at > 5 years [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Assess if the use of adjuvant radiotherapy improve outcome in patients with primary mediastinal lymphoma treated initially with R-CHOP


Secondary Outcome Measures:
  • assess toxicity secondary to mediastinal radiotherapy [ Time Frame: > 5 years ] [ Designated as safety issue: No ]
    Assess if the addition of mediastinal radiotherapy to patients who received anthracyclines can produce an increase in cardiac toxicity


Enrollment: 198
Study Start Date: June 2002
Study Completion Date: December 2009
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Radiotherapy in mediastinal lymphoma
Adjuvant radiotherapy or not (control group) in patients treated with R-CHOP
Radiotherapy in mediastinal lymphoma
Radiotherapy will no be administered in patients treated with R-CHOP
Radiotherapy in primary mediastinal lymphoma
Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site.
Radiation: no drugs
Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP
Other Name: no applicable

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with primary mediastinal lymphoma treated in an tertiary medical center

Criteria

Inclusion Criteria:

Diagnosis of primary mediastinal lymphoma No previous treatment performance status < 2 HIV, Hepatis B and C negative Normal :Renal, hepatic, pulmonary and cardiac function

Exclusion Criteria:

pregnancy

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01230008

Locations
Mexico
Oncology Research Unit
Mèxico DF, DF, Mexico, 06725
Sponsors and Collaborators
Instituto Mexicano del Seguro Social
  More Information

No publications provided

Responsible Party: Agustin Aviles, Mexican Institute of Social Security
ClinicalTrials.gov Identifier: NCT01230008     History of Changes
Other Study ID Numbers: katty7, katt7
Study First Received: October 27, 2010
Last Updated: October 27, 2010
Health Authority: Mèxico: National Research Counsil, Instituto Mexicano del Seguro Social

Keywords provided by Instituto Mexicano del Seguro Social:
primary mediastinal lymphoma
radiotherapy
chemotherapy
rituximab

Additional relevant MeSH terms:
Lymphoma
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on October 23, 2014